Patient Opportunity Trust
Advisor Managed Portfolios · 6 share classes
Fund classification
Classified from what the fund holds · as of 2026 Q2
Patient Opportunity Trust is an actively managed U.S. equity fund.
- Asset class
- Equity
- Region
- United States
- Management
- Actively managed
- Fund type
- Open-end fund
- Features
- Non-diversified
Fund profile
As filed in the prospectus · 2026 Q2
The Patient Opportunity Trust (the Fund) seeks long term growth of capital.
The fund seeks long-term capital growth by identifying and exploiting what its manager believes are mispricings and inefficiencies across global markets, without restriction by investment style or asset class; it may hold equities of any size, debt securities including high-yield, derivatives, short positions, and up to 15% in cryptocurrency exchange-traded products. The fund is non-diversified and may concentrate assets in a smaller number of issuers. To access cryptocurrency and commodity derivatives while meeting regulatory requirements, the fund may invest up to 25% of assets in a wholly-owned Cayman Islands subsidiary that holds these exposures directly.
| Share class | Gross | Net |
|---|---|---|
| LMORX | 1.94% | 1.94% |
| LMOFX | 1.74% | 1.74% |
| LGOAX | 1.69% | 1.69% |
| LMNOX | 1.44% | 1.39% |
| LMOPX | 2.44% | 2.44% |
| MVISX | 1.33% | 1.33% |
Net is what a holder pays after the adviser's contractual waiver; gross is before it. A waiver can expire.
Portfolio turnover 27.00% · as of 2026 Q2
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 105.43% |
| Derivatives | 4.84% |
These positions come to 110.27% of the fund's net assets. This counts only what the fund reported holding — the holdings disclosure covers assets, not liabilities such as borrowings — so it is not expected to reconcile to 100%.
Derivatives are shown at market value, not notional exposure.
Sector allocation
The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2
| Health Care | 23.8% |
| Financials | 19.9% |
| Communication Services | 12.3% |
| Consumer Discretionary | 10.9% |
| 5 smaller | 33.1% |
Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).
Latest quarter
What changed since the fund's previous filing
New: GPN, Fidelity Wise Origin Bitcoin F, Adyen NV, QXO INC, Genius Sports Ltd
Exited: iShares Bitcoin Trust ETF, Noble Corp PLC, PLAY
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
| Share class | 1-year | 3-year | 5-year | Vol | Worst fall |
|---|---|---|---|---|---|
| +56.38% | — | — | 19.16% | — | |
| +56.67% | — | — | 19.15% | — | |
| +56.76% | — | — | 19.16% | — | |
| +57.23% | — | — | 19.15% | — | |
| +55.56% | — | — | 19.14% | — | |
| +57.32% | — | — | 19.16% | — |
These classes hold the same portfolio, so the 1.76pp spread over 1 year is the cost difference between them — roughly 1.76pp a year — not a difference in what they own.
May 2026 and Jun 2026 have been filed since the trailing figures were struck, so they are not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| — | Royalty Pharma PLC | 6.98% | $56.07 | $140.18M | 2.5M |
| C | Citigroup IncC | 6.97% | $139.96 | $139.96M | 1.0M |
| GOOGL | Alphabet IncGOOGL | 6.67% | $357.37 | $134.01M | 375.0K |
| UNH | UnitedHealth Group IncUNH | 6.21% | $415.63 | $124.69M | 300.0K |
| AMZN | Amazon.com IncAMZN | 5.64% | $238.34 | $113.21M | 475.0K |
| NVDA | NVIDIA CorpNVDA | 4.98% | $200.09 | $100.05M | 500.0K |
| CVS | CVS Health CorpCVS | 4.51% | $103.45 | $90.52M | 875.0K |
| QXO | QXO IncQXO | 4.47% | $17.28 | $89.86M | 5.2M |
| — | Norwegian Cruise Line Holdings | 4.21% | $21.11 | $84.44M | 4.0M |
| — | Precigen Warrant Restricted | 4.19% | — | $84.18M | — |
Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.
Top 10 positions are 54.84% of net assets, top 25 96.72%, across 38 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free